Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/2b99c525-a76a-4b04-bbcb-e6bb713af621/

NAGE

Niagen Bioscience, Inc.
Chart
$3.45
Latest Week 2026-06-05
Snapshot 2026-06-07 · 0.0w · Fresh
0.08
OS Score
15.0%
Value
71.0%
Quality
1.0%
Momentum
5/9
F-Score
0.326
QV
Strategy Eligibility
2 of 23 passing
OS Composite
Trending Value
Quality × Value
🏛
Cornerstone Value
🌿
Cornerstone Growth
💎
Deep Value
VC2 Cheapest
📐
EBITDA/EV
Veiled Value
Piotroski Bargains
🔬
Quality Compounders
ROE 23%
📈
Consistent Earners
🌱
GARP
Rev +21%
🔄
Shareholder Yield
💰
High Yield
🚀
Momentum Leaders
Market Leaders
Tiny Titans
🔍
Small Cap Value
🛡
Low Volatility
🏷
Sector Cheapest
🧠
Capital Allocators
Risk-Adj Momentum
V
Value Analysis
Cheapness relative to fundamentals
15.0%ile
P/E
15.7×
P/S
2.2×
P/B
3.5×
E/P
0.0639
FCF Yield
0.021
EBITDA/EV
0.059
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
84.00000000
/100 — 1=cheapest
VC2 (Trending Value)
86.00000000
/100
VC3 (Buyback)
86.00000000
/100
VC2 score of 86.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
71.0%ile
ROE
0.226
ROA
0.163
Net Margin
0.143
Op Margin
0.089
GPA
0.733
D/E
0.39
Current
4.61
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.208
Earn Growth
0.321
Stability
0.567
lower=better
Accruals
0.125
lower=better
5yr Consist
No
ROE of 23% is exceptional. Conservative balance sheet with D/E of 0.39. Accruals ratio of 0.125 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
1.0%ile
6M Return
-46.5%
12M Return
-73.4%
12-1 Mom
-67.8%
Risk-Adj
-1.38
Vol 252d
49.1%
Vol 60d
112.3%
↑ Expanding
Max DD 12M
-75.7%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -68% signals a downtrend — price is moving against you. Near-term vol (112%) is expanding vs long-term (49%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.08
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
Sector Context
Healthcare · 500 peers
Sector Value %ile
5.2%
Sector Quality %ile
82.6%
P/E z-score
-0.18
P/B z-score
-0.12
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Growth at Reasonable Price
Revenue growing 21% with P/E of 16×. Growth isn't fully priced in.
Earnings Quality Concern
ROE looks strong (23%) but high accruals (0.125) suggests earnings are accrual-heavy, not cash-backed.
Quality at a Premium
High quality (71th) but expensive (15th value). Upside may be limited without earnings growth.
Volatility Expanding
60-day vol (112%) significantly exceeds 252-day (49%). Near-term risk is elevated.
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
C
47.8% avg (7 factors)
Quality
B
68.8% avg (8 factors)
Momentum
F
0.0% avg (4 factors)
Risk
D
34.8% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.080—1
Value %ile0.150—1
Quality %ile0.710—1
Momentum %ile0.010—1
F-Score5.000—0
Confidence1.000—1
Volatility0.491—1
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
15.65
Earnings Yield (E/P)
0.0639
Price / Sales
2.24
Price / Book
3.54
Price / Cash Flow
66.73
FCF Yield
2.1%
EBITDA / EV
5.9%
Sales Yield (1/P·S)
0.5765
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
22.6%
Return on Assets
16.3%
Net Margin
14.3%
Operating Margin
8.9%
Gross Profit / Assets
Novy-Marx GPA
73.3%
Debt / Equity
0.39
Current Ratio
4.61
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.125
MomentumPrice trend strength over different horizons
6M Return
-46.5%
12M Return
-73.4%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-67.8%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-1.38
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
20.8%
Earnings Growth (YoY)
32.1%
Earnings Stability (CV)
Lower = more stable
0.567
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
5
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
84
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
86
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
86
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity